Impact News +++ Insiderhandel: Vorstand kauft Aktien von SBF im Wert von 12000 EUR (Insiderkauf) +++ SBF AG Aktie -4,13%

Foren & Soziale Netzwerke zur ANAPTYSBIO Aktie

>ANAPTYSBIO Aktienkurs

50.74 EUR +5.8% (TradegateBSX)

Ask: 50.76 EUR / 99 Stück

Bid: 49.52 EUR / 101 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ANAPTYSBIO Aktie über LYNX handeln

Intraday

1 Jahr

>ANAPTYSBIO Performance

1 Woche: +5,4%

1 Monat: -2,2%

3 Monate: -2,2%

6 Monate: -9,5%

1 Jahr: +176,2%

laufendes Jahr: +12,6%

>ANAPTYSBIO Aktie

Profil:

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfuncti..
>Volltext..

Insiderhandel:

>ANAPTYSBIO Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>ANAPTYSBIO Peer Group

Gesundheit, Antikörper- Behandlung, Rheuma- Behandlung, Hauterkrankungen & -behandlung/ Dermatologie, Magen-Darm-Erkrankungen & -behandlung
>Alle Branchen..

>ANAPTYSBIO Chart & Kurs - NASDAQ

>ANAPTYSBIO in Foren & Soziale Netzwerke

28.04.26 - 15:33	SVB_Leerink_LLC: buy AnaptysBio Inc (Sharewise)
	Kursziel: 72.5645 €

22.04.26 - 15:33	Barclays_PLC: buy AnaptysBio Inc (Sharewise)
	Kursziel: 53.6445 €

31.03.26 - 18:03	Piper_Sandler: buy AnaptysBio Inc (Sharewise)
	Kursziel: 82.764 €

30.03.26 - 15:18	HC_Wainwright: buy AnaptysBio Inc (Sharewise)
	Kursziel: 57.3078 €

17.03.26 - 17:48	UBS_Group_AG: buy AnaptysBio Inc (Sharewise)
	Kursziel: 78.282 €

12.03.26 - 16:33	Wedbush: buy AnaptysBio Inc (Sharewise)
	Kursziel: 65.025 €

05.03.26 - 15:03	Stifel_Nicolaus: buy AnaptysBio Inc (Sharewise)
	Kursziel: 73.1255 €

04.03.26 - 16:03	Barclays_PLC: buy AnaptysBio Inc (Sharewise)
	Kursziel: 68.1138 €

12.01.26 - 06:21

ANAB (USA) - Biotech Momentum Testing Major Support (TradingView)

AnaptysBio Inc has been on a good run this year with a gain of over 200% . Based in San Diego, this clinical-stage biotech focuses on developing antibody therapeutics for inflammatory diseases. When a stock runs this hard, it eventually needs a bit of a pullback to get back into a better value area for investors, and that is exactly what we are seeing on the chart right now. Fundamentally, the momentum here has been driven by optimism around their immunology pipeline, particularly for rheumatoid arthritis , and the planned separation of their royalty business . The recent dip looks like standard profit-taking after such an extended move, perhaps nudged by some insider selling earlier in January. The core thesis of strong royalties plus clinical upsidestill seems good. Technically, the price action is cleaning up nicely. The stock has pulled back right into the 50-day SMA (the orange line), which often acts as a natural floor for strong uptrends. The RSI has reset from overbought levels down to a neutral

18.12.25 - 15:18	Guggenheim: buy AnaptysBio Inc (Sharewise)
	Kursziel: -

11.11.25 - 16:18	Barclays_PLC: buy AnaptysBio Inc (Sharewise)
	Kursziel: 60.585 €

10.11.25 - 20:18	Wedbush: buy AnaptysBio Inc (Sharewise)
	Kursziel: -

05.11.25 - 16:18	Guggenheim: buy AnaptysBio Inc (Sharewise)
	Kursziel: 87.01 €

05.11.25 - 16:18	Wells_Fargo___Compan: buy AnaptysBio Inc (Sharewise)
	Kursziel: 70.4781 €

30.09.25 - 15:03	Wedbush: buy AnaptysBio Inc (Sharewise)
	Kursziel: 38.394 €

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werde nie so reich an Geist, dass arm Du würdest am Herzen! - Otto Ludwig

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram